The Evolution of HTA in Emerging Markets Health-Care ... - TREE

More documents

Recommendations

Info

OHE Consulting Report for PhRMA 5 January 2011 A4.5 Information use (ability to learn with/from other countries also developing or having developed HTA and use of information from internal organisations) a. Which other country/countries do you think have relevant or useful HTA approaches—that China/Brazil/Taiwan might want to follow or learn from-‐and why? b. What are the key links between the HTA body/bodies and academic/research institutions? A4.6 Challenges a. What are the three main challenges which the healthcare system in China/Brazil/Taiwan has recently faced or is currently encountering? b. Did HTA have a role to play in addressing any of these? c. Looking forward, what are the three main challenges the healthcare system in China/Brazil/Taiwan is likely to face in the next five years? d. Does HTA have a role to play in addressing any of these? A4.7 Stakeholders and the policy debate a. Is there an active debate or discussion about the form and evolution of HTA in China/Brazil/Taiwan? b. If so, who are the key stakeholders in the policy discussion, and what are their positions? A4.8 Literature a. What do you feel are the most relevant reports and material which outline HTA in your country, including published and unpublished, peer-‐reviewed and grey literature? 106
OHE Consulting Report for PhRMA 5 January 2011 Appendix 5: Interview Programme The Table below represents local experts identified as potential targets to interview for each country. In total 19 experts were interviewed from this list across the three countries. For China the names highlighted in bold represent those whom were interviewed. For Brazil the interviews were conducted on the basis of non-‐disclosure of their names. Similarly for Taiwan, those names represent those determined as potential targets for interview, but the specific subset who was interviewed has not been disclosed. China Academic Government Industry Other Dr. Gordon Liu, Professor of Economics, Guanghua School of Management, Peking University. Dr. Shanlian Hu, Professor of Epidemiology and Health Management, School of Public Health, Fudan University Dr. Zhenzhong Zhang, Director of China Health Economics Institute, Ministry of Health. Lu Fengxia, Chairman, Drug Price Evaluation Center, NDRC Dr. Vivian Chen, Director of Healthcare Economics, R&D-‐based Pharmaceutical Association Committee Dr. Chuan Chen, Director of Government Affairs, Xian-‐Janssen Pharmaceutical Ltd. Dr. Jiuhong Wu, Director of Pharmacy Department, the 306th Hospital of PLA. Ashoke Bhattacharjya within JnJ. He is within the Health Policy team Manny Papadimitropoulos (Regional Director of Health Outcomes for Lilly in Emerging Bill Montgomery and / or Narayan Rajan (works out of Australia for Manny and also has great technical knowledge of these developing markets) Guang Zhiqiang, GAD, Pfizer David Banta – although not based in China, helped establish HTA in China 107
Page 1 and 2:
Consulting Report 1 The Evolution
Page 3 and 4:
OHE Consulting Report for PhRMA 5 J
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56: OHE Consulting Report for PhRMA 5 J
Page 105: OHE Consulting Report for PhRMA 5 J
Page 119: OHE Consulting Report for PhRMA 5 J
show all

The Evolution of HTA in Emerging Markets Health-Care ... - TREE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?